Suppr超能文献

[脑室内纤溶治疗继发性脑室内出血的有效性和安全性(一项前瞻性随机研究)]

[Effectiveness and safety of intraventricular fibrinolysis in secondary intraventricular hemorrhages (a prospective, randomized study)].

作者信息

Gubucz István, Kakuk Ilona, Major Ottó, Szegedi Norbert, Barsi Péter, Pánczél Gyula, Varga Dániel, Ovary Csaba, May Zsolt, Ricsói Gabriella, Kenéz Júlia, Szilágyi Géza, Nagy Zoltán

机构信息

Agyérbetegségek Országos Központja, Országos Pszichiatriai és Neurológiai Intézet, Budapest.

出版信息

Orv Hetil. 2004 Aug 1;145(31):1609-15.

Abstract

BACKGROUND AND PURPOSE

Intraventricular clot secondary to brain hemorrhage has still one of the worst prognosis among all stroke subtypes, regardless of conservative therapy or surgical interventions. The rapid clot resolution with thrombolytic agents could improve the outcome by restoring the impaired cerebrospinal fluid circulation, for this reason, the authors examined the safety and efficacy of Urokinase therapy in a randomized, controlled study.

METHODS

They enrolled 27 patients with severe intraventricular hemorrhage between 1998 and 2002. All patients had supratentorial intracerebral hemorrhage caused by hypertension, with IVH, moreover clinically worsening course due to the obstructive hydrocephalus confirmed by CT. Eleven persons were treated with ventriculostomy alone and 16 received adjunctive intraventricular urokinase. The authors examined the early, 30-day and 1-year mortality, furthermore the neurological (Scandinavian Stroke Scale) and functional outcome (Barthel Scale). The mean age was 60 +/- 9.5. The initial Scandinavian Stroke Scale was 7.51 +/- 8.64, Glasgow Coma Scale was 6.85 +/- 2.52, intracerebral hemorrhage volume was 22.44 +/- 18.14 ml.

RESULTS

The 1 year survival rate was significant higher in the urokinase treated group (p = 0.014), This tendency in the mortality (31.3% vs. 54.5%) and in the neurological/functional condition (SSS, p = 0.078/Barthel, p = 0.119) at 30th day have been also documented. No hemorrhagic complications due to urokinase were observed. Two meningitis (7.4%) and two intraparenchymal hemorrhages (7.4%) related to drain insertion were detected (p = 0.009). The probability of pulmonary infection was roughly two times higher in the group without clot lysis (RR = 1.870; 95% CI: 1.004-3.482).

CONCLUSIONS

In the authors experience, urokinase treatment reveals to be safe in the intraventricular clot lysis. This therapy allows earlier mobilization and rehabilitation, and decreases the number of infections, which are favorable to the long-term survival rate.

摘要

背景与目的

脑出血继发脑室积血在所有卒中亚型中预后仍然最差,无论采用保守治疗还是手术干预。使用溶栓药物快速溶解血凝块可通过恢复受损的脑脊液循环改善预后,因此,作者在一项随机对照研究中检验了尿激酶治疗的安全性和有效性。

方法

1998年至2002年期间,他们纳入了27例重度脑室出血患者。所有患者均为高血压所致幕上脑出血伴脑室积血,且经CT证实因梗阻性脑积水导致临床病情恶化。11例患者仅接受脑室造瘘术治疗,16例接受了辅助性脑室内尿激酶治疗。作者检查了早期、30天和1年死亡率,以及神经功能(斯堪的纳维亚卒中量表)和功能结局(巴氏量表)。平均年龄为60±9.5岁。初始斯堪的纳维亚卒中量表评分为7.51±8.64,格拉斯哥昏迷量表评分为6.85±2.52,脑出血量为22.44±18.14ml。

结果

尿激酶治疗组1年生存率显著更高(p = 0.014),第30天时死亡率(31.3%对54.5%)以及神经功能/功能状况(斯堪的纳维亚卒中量表,p = 0.078/巴氏量表,p = 0.119)也有这种趋势。未观察到因尿激酶引起的出血并发症。检测到2例与引流管插入相关的脑膜炎(7.4%)和2例脑实质内出血(

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验